Trading Signals: UTHR Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Fri. Dec. 22, 2023)( United Therapeutics Corp)
| UTHR latest price $147.1900 (-0.57%) ($146.6000 - $149.6400) on Thu. Mar. 2, 2017. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.67% (three month average) | RSI | 29 | Latest Price | $147.1900(-0.57%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | UTHR declines -5.3% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support UTHR advance at 0% a week (0% probability) IBB(44%) XBI(42%) XLV(42%) VT(38%) VYM(38%) | Factors Impacting UTHR price | UTHR will decline at least -1.335% in a week (0% probabilities). VIXM(-15%) TLT(-13%) UUP(-7%) IPO(-2%) BNDX(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.335% (StdDev 2.67%) | Hourly BBV | 0 () | Intraday Trend | -0.8% | | | |
|
Resistance Level | $159.03 | 5 Day Moving Average | $148.43(-0.84%) | 10 Day Moving Average | $153.65(-4.2%) | 20 Day Moving Average | $159.03(-7.45%) | To recent high | -12.6% | To recent low | 16.4% | Market Cap | $6.529b | | | | United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD. |